These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

769 related items for PubMed ID: 35451945

  • 21. Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018.
    Shortridge D, Streit J, Pfaller M, Tulloch M, Chen WT, Castanheira M.
    J Glob Antimicrob Resist; 2022 Dec; 31():98-103. PubMed ID: 35988706
    [Abstract] [Full Text] [Related]

  • 22. In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.
    Goodlet KJ, Nicolau DP, Nailor MD.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [Abstract] [Full Text] [Related]

  • 23. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A, Tan E, McCarthy KL, Paterson DL.
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [Abstract] [Full Text] [Related]

  • 24. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa.
    Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, Hu F, China Antimicrobial Surveillance Network (CHINET) Study Group.
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30617091
    [Abstract] [Full Text] [Related]

  • 25. Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016.
    Kuo SC, Liu CE, Lu PL, Chen YS, Lu MC, Ko WC, Hsueh PR, Chuang YC, Wang FD, SMART Asia-Pacific Group.
    Int J Antimicrob Agents; 2020 Mar; 55(3):105883. PubMed ID: 31923574
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016 and 2019 in China.
    Yu W, Zhang H, Zhu Y, Jia P, Xu Y, Yang Q.
    Int J Antimicrob Agents; 2023 Apr; 61(4):106741. PubMed ID: 36736928
    [Abstract] [Full Text] [Related]

  • 31. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).
    Pfaller MA, Shortridge D, Sader HS, Flamm RK, Castanheira M.
    J Glob Antimicrob Resist; 2017 Sep; 10():186-194. PubMed ID: 28735046
    [Abstract] [Full Text] [Related]

  • 32. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS, Farrell DJ, Flamm RK, Jones RN.
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [Abstract] [Full Text] [Related]

  • 33. In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program.
    Karlowsky JA, Hackel MA, Wise MG, Six DA, Uehara T, Daigle DM, Cusick SM, Pevear DC, Moeck G, Sahm DF.
    Antimicrob Agents Chemother; 2023 Jan 24; 67(1):e0128122. PubMed ID: 36541767
    [Abstract] [Full Text] [Related]

  • 34. Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: Results from the study for monitoring antimicrobial resistance trends (SMART - Brazil; 2016-2017).
    Beirão EM, Rodrigues SDS, Andrade TK, Serra FB, Paula MDN, Polis TJB, Gales AC.
    Braz J Infect Dis; 2020 Jan 24; 24(4):310-321. PubMed ID: 32663440
    [Abstract] [Full Text] [Related]

  • 35. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
    Meletiadis J, Paranos P, Georgiou PC, Vourli S, Antonopoulou S, Michelaki A, Vagiakou E, Pournaras S.
    Int J Antimicrob Agents; 2021 Nov 24; 58(5):106440. PubMed ID: 34551356
    [Abstract] [Full Text] [Related]

  • 36. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021.
    Karlowsky JA, Lob SH, Hawser SP, Kothari N, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF.
    Eur J Clin Microbiol Infect Dis; 2024 Jul 24; 43(7):1343-1348. PubMed ID: 38775873
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ, Sader HS, Flamm RK, Jones RN.
    Int J Antimicrob Agents; 2014 Jun 24; 43(6):533-9. PubMed ID: 24856078
    [Abstract] [Full Text] [Related]

  • 39. Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
    Gill CM, Nicolau DP, ERACE-PA Global Study Group.
    J Antimicrob Chemother; 2022 Dec 23; 78(1):252-256. PubMed ID: 36411249
    [Abstract] [Full Text] [Related]

  • 40. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).
    Sader HS, Flamm RK, Carvalhaes CG, Castanheira M.
    Diagn Microbiol Infect Dis; 2020 Mar 23; 96(3):114833. PubMed ID: 31924426
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.